Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10187549 | 0.86 | CYP17A1 (0.43) | CYP17A1CYP1A2SLC2A1SLC2A2TRPV1 | |
| SCHEMBL10187420 | 0.81 | CYP17A1 (0.60) | CYP17A1EPHX2GAACYP1A2SLC2A1 | |
| SCHEMBL368116 | 0.76 | CYP17A1 (0.71) | CYP17A1CYP1A2 | |
| SCHEMBL367430 | 0.73 | CYP17A1 (1.00) | CYP17A1CYP1A2 | |
| SCHEMBL15113007 | 0.73 | SLC2A1 (0.46) | CYP17A1GAACYP1A2SLC2A1SLC2A2 | |
| SCHEMBL368630 | 0.73 | CYP17A1 (0.42) | CYP17A1CYP1A2SLC2A1SLC2A2 | |
| SCHEMBL368955 | 0.71 | CYP17A1 (0.57) | CYP17A1CYP1A2NPC1RAB9A | |
| SCHEMBL367468 | 0.70 | CYP17A1 (0.53) | CYP17A1CYP1A2SLC2A1SLC2A2 | |
| SCHEMBL368885 | 0.69 | CYP17A1 (0.41) | CYP17A1CYP1A2SLC2A1SLC2A2 | |
| SCHEMBL2897752 | 0.69 | EPHX2 (0.47) | CYP17A1EPHX2GAAHSD11B1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2593453-B1 | AZAINDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673922-B2 | Azaindazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2013-07-18 | — | — | US | disclosed |
| WO-2012009510-A1 | AZAINDAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184254-A1 | AZAINDAZOLE COMPOUNDS | CYP3A4, CYP4B1, CYP3A43 | CYP17A1 53/4885EPHX2 1549/4885GAA 1323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.